GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (FRA:PF0) » Definitions » Other Operating Expense

NetraMark Holdings (FRA:PF0) Other Operating Expense : €0.10 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings Other Operating Expense?

NetraMark Holdings's Other Operating Expense for the three months ended in Dec. 2023 was €0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €0.10 Mil.

NetraMark Holdings's quarterly Other Operating Expense declined from Mar. 2023 (€0.10 Mil) to Sep. 2023 (€0.00 Mil) but then stayed the same from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

NetraMark Holdings's annual Other Operating Expense increased from Sep. 2021 (€0.00 Mil) to Sep. 2022 (€0.45 Mil) but then declined from Sep. 2022 (€0.45 Mil) to Sep. 2023 (€0.42 Mil).


NetraMark Holdings Other Operating Expense Historical Data

The historical data trend for NetraMark Holdings's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings Other Operating Expense Chart

NetraMark Holdings Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Other Operating Expense
- - 0.45 0.42

NetraMark Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.11 0.10 - -

NetraMark Holdings Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NetraMark Holdings Other Operating Expense Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


NetraMark Holdings (FRA:PF0) Business Description

Traded in Other Exchanges
Address
1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.

NetraMark Holdings (FRA:PF0) Headlines

No Headlines